Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
competitor Processed

Hims & Hers Health & Novo Nordisk

4 shared events · Importance 3 · Last updated Feb 09, 2026

Importance
3
Shared Events
4
Actions
5
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard

Hims & Hers Health is facing legal threats from Novo Nordisk after their brief distribution partnership was terminated over the telehealth platform's sale of compounded Semaglutide knockoffs.

45
Regulatory
Hims & Hers Health: Hims & Hers is the central defendant in the securities class action and the FTC lawsuit, facing allegations of deceptive practices that have already caused a significant stock drop and reputational damage. The outcome could result in financial penalties and changes to its business operations.
Novo Nordisk: Novo Nordisk previously sued Hims & Hers for patent infringement over compounded GLP-1 drugs but later dropped the lawsuit and agreed to have its branded drugs sold on Hims' platform.
Jul 29, 2026 · 215 articles
0
Regulatory
Hims & Hers Health: Hims & Hers Health dropped its plan to offer a compounded version of Wegovy after the FDA threatened action, leading to a 14% drop in its stock. This decision impacts its strategy in the weight-loss medication market.
Feb 07, 2026 · 6 articles
0
Business
Hims & Hers Health: Hims & Hers Health launched a cheaper, off-brand version of Semaglutide, capitalizing on the demand for GLP-1 drugs, which led to legal threats from Novo Nordisk.
Feb 05, 2026 · 6 articles
0
Business
Hims & Hers Health: Hims & Hers Health is advertising its GLP-1 weight loss drugs, emphasizing access to healthcare, and participating in the health and telehealth advertising trend.
Feb 04, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Hims & Hers Health and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.